Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NK Cell Immunotherapy with Cetuximab in Metastatic GI Cancer
NCT02845999Phase 1Completed
- Sponsor
- CHU de Besançon
- Start
- Nov 2009
- Primary completion
- Jan 2013
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of JD002 in gastrointestinal cancer, sponsored by CHU de Besançon. Primary endpoint: Number of patients with clinical or biological grade 3 or 4 treatment-related adverse events at 6 weeks. Started Nov 2009; status: completed.
02
Drugs
JD002
03
Conditions
gastrointestinal cancer
Beyond the preview
Go deeper on NCT02845999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02845999.